Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hyperpolarization-activated Cyclic Nucleotide-gated ion channel 2 (HCN2) is a voltage-gated cation channel that mediates the hyperpolarization-activated current, often referred to as the 'funny' current (If) in the heart or the h-current (Ih) in the brain [6, 9, 11]. Unlike most voltage-gated channels, HCN2 opens upon membrane hyperpolarization and is further modulated by the binding of cyclic nucleotides, such as cAMP, which shifts its activation threshold to more depolarized potentials [6, 13]. It is highly expressed in the thalamus, cortex, and peripheral sensory neurons, where it plays a fundamental role in maintaining the resting membrane potential and regulating rhythmic neuronal firing [3, 15]. In pathological contexts, HCN2 has been identified as a critical 'pacemaker for pain,' particularly in neuropathic and inflammatory states where its sensitization by cAMP leads to spontaneous firing in nociceptive fibers [5, 13]. Furthermore, genetic variants in the HCN2 gene are linked to several forms of epilepsy and severe neurodevelopmental disorders, including febrile seizures and developmental encephalopathy [16, 17]. This makes HCN2 a significant therapeutic target for the development of selective analgesics and anticonvulsants that aim to stabilize neuronal excitability by modulating the channel's gating properties [13, 20].
HCN channel blocker, HCN channel inhibitor, HCN channel partial agonist
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hyperpolarization-activated Cyclic Nucleotide-gated ion channel 2 (HCN2).